期刊文献+

液-质联用法同时测定人血浆中霉酚酸及其代谢物浓度及其在肝移植患者药动学研究中的应用 被引量:5

Determination of mycophenolic acid and its metabolites in plasma by liquid chromatographic-tandem mass spectrometry and application in pharmacokinetic study in liver transplant patients
原文传递
导出
摘要 目的:建立LC-MS/MS法同时测定血浆中霉酚酸(MPA)及其代谢物MPAG与AcMPAG浓度,用于治疗药物监测与药动学研究。方法:100μl血浆标本加入300μl含内标吲哚美辛的乙腈沉淀,离心后取上清液进样。色谱柱为Agilent E-clipse XDB-C18柱(3.5μm,2.1 mm×100 mm),流动相为2 mmol·L-1甲酸铵水溶液-甲醇,采用梯度洗脱的方法,流速0.3 ml·min-1。用多反应监测进行定量,ESI负离子方式进行检测,用于定量分析的检测离子分别为m/z319.1→274.9(MPA)、m/z495.3→174.4(MPAG与AcMPAG)与m/z 356.1→312.0(内标吲哚美辛)。24例肝移植患者,采用包括霉酚酸钠肠溶片(EC-MPS)的三联免疫抑制方案,测定服药后MPA及其代谢物浓度并计算药动学参数。结果:MPA在0.10~50.5μg·ml-1,MPAG在1.13~4501μg·ml-,AcMPAG在0.11~22.4μg·ml-1范围内线性良好(r2〉0.99)。MPA、MPAG、AcMPAG提取回收率为77.3%~92.6%;基质效应为76.0%~86.7%;回收率为94.2%~116.4%;日内及日间变异均小于15%。24例肝移植患者用药1周后MPA、MPAG、AcMPAG的主要药动学参数分别如下:峰浓度Cmax为(18.8±10.9),(154±118),(3.07±2.85)μg·ml-1;达峰时间Tmax为(3.82±2.66),(4.74±2.51),(4.51±2.72)h;曲线下面积AUC0-12为(45.2±20.3),(1 456±1 195),(18.3±16.2)μg·h·ml-1;消除半衰期t1/2为(3.21±2.56),(9.26±4.33),(5.57±5.76)h。结论:本研究所建立的方法快速准确、灵敏、专属性强,适用于MPA及其代谢物的血药浓度监测和人体药动学研究。 OBJECTIVE To establish an LC-MS/MS method for the determination of mycophenolic acid(MPA)and its metabolites MPAG and AcMPAG in human plasma and investigate the pharmacokinetic characteristics in Chinese liver-transplanted patients.METHODS 300μl of acetontrile containing indomethacin(internal standard)was added in100μl plasma to precipitate protein.After centrifugation,the supernatant was eluted through Agilent Eclipse XDB-C18(3.5μm,2.1 mm×100mm)column by water(2 mmol·L-1 ammonium acetate)-methanol through a gradient assay,the flow rate was set as 0.3 ml·min-1.Electrospray ionization(ESI)source was applied and operated in the negative ion mode.Multiple reaction monitoring(MRM)mode with the transition of m/z319.1→274.9(MPA),495.3→174.4(MPAG and AcMPAG)and 356.1→312.0(IS)was used for quantification.Plasma concentration of MPA,MPAG,AcMPAG of 24 liver-transplanted patients received immunosuppressive therapy including enteric-coated mycophenolate sodium were determined and pharmacokinetic parameters were calculated.RESULTS The method was proved to be linear in the range of 0.10-50.5μg·ml-1 for MPA,1.13-450μg·ml-1 for MPAG,0.11-22.4μg·ml-1 for AcMPAG(r2〉0.99).The extract recovery,matrix effect,recovery of MPA and its metabolites was 77.3%-92.6%,76.0%-86.7% and 94.2%-116.4%,respectively.The within-day and between-day variation were both lower than15%.The pharmacokinetic parameters of MPA and its metabolites of 24 liver transplant patients were as follows:Cmax:(18.8±10.9),(154±118),(3.07±2.85)μg·ml-1;tmax:(3.82±2.66),(4.74±2.51),(4.51±2.72)h;AUC0-12:(45.2±20.3),(1 456±1 195),(18.3±16.2)μg·h·ml-1;t1/2:(3.21±2.56),(9.26±4.33),(5.57±5.76)h,respectively.CONCLUSION The method established is rapid,accurate,sensitive and specific,which is suitable for the therapeutic drug monitoring(TDM)and pharmacokinetic study of MPA and its metabolites.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2015年第23期2096-2101,共6页 Chinese Journal of Hospital Pharmacy
基金 国家自然科学基金(编号:81473275) 上海市自然科学基金(编号:12ZR1418900)
关键词 LC-MS/MS法 霉酚酸(MPA) MPAG AcMPAG 药动学 LC-MS/MS mycophenolic acid(MPA) MPAG AcMPAG Pharmacokinetics
  • 相关文献

参考文献12

  • 1Schutz E, Shipkova M, Armstrong VW, et al. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil[J]. Clin Chem,1999,45(3):419-422.
  • 2Bullingham R, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil[J]. Clin Pharmacokinet,1998,34:429-455.
  • 3Shaw LM, Nicholls A, Hale M, et al. Therapeutic monitoring of mycophenolic acid:a consensus panel report[J]. Clin Biochem,1998,5:317-322.
  • 4Schutz E, Shipkova M, Armstrong VW, et al. Therapeutic drug monitoring of mycophenolic acid:comparison of HPLC and immunoassay reveals new MPA metabolites[J]. Transplant Proc,1998,30(4):1185-1187.
  • 5Holt DW. Monitoring mycophenolic acid[J]. Ann Clin Biochem,2002,39(3):173-183.
  • 6Beal JL, Jones CE, Taylor PJ, et al. Evaluation of an immunoassay(EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay[J]. Ther Drug Monit,1998,20:685-690.
  • 7Shipkova M, Schutz E, Armstrong VW, et al. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit[J]. Clin Chem,2000,46(3):365-372.
  • 8Patel CG, Akhlaghi F. High-performance liquid chromatography method for the determination of mycophenolic acid and its acyl and phenol glucuronide metabolites in human plasma[J]. Ther Drug Monit,2006,28(1):116-122.
  • 9Chen B, Zhang WX, Yu ZC, et al. Determination of Mycophenolic Acid(MPA) and Its Acyl and Phenol Glucuronide Metabolits Simultaneously in Human Plasma by a Simplified HPLC Method[J]. Analytical Letter,2007,40:2465-2475.
  • 10Brandhorst G, Streit F, Goetze S, et al. Quantification by liquid chromatography tandem mass spectrometry of mycophenolic acid and its phenol and acyl glucuronide metabolites[J]. Clin Chem,2006,52(10):1962-1964.

同被引文献45

引证文献5

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部